BMO Capital analyst Matt Borsch raised his price target on Molina Healthcare to $105, saying the stock should trade higher following the "surprise" decision by Florida regulators to allow the company to continue serving the Florida Medicaid market under new contracts effective in 2019. The analyst notes that Molina had been expected to lose all of its Florida Medicaid business, but will now retain most of its regions. Borsch keeps his Market Perform rating, adding that while he is raising his FY19 revenue projections, he is keeping his EPS forecast at $5.00 because the Florida market is not currently profitable.